Pasithea Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • KTTA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.47
  • (As of Thursday Closing)

Pasithea Therapeutics General Information

Description

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Corporate Office
  • 1111 Lincoln Road
  • Suite 500
  • Miami Beach, FL 33139
  • United States
+1 (786)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1111 Lincoln Road
  • Suite 500
  • Miami Beach, FL 33139
  • United States
+1 (786)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pasithea Therapeutics Stock Performance

As of 19-Nov-2026, Pasithea Therapeutics’s stock price is $0.47. Its current market cap is $17.7M with 36.8M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.47 $0.51 $0.28 - $2.06 $17.7M 36.8M 709K -$1.38

Pasithea Therapeutics Financials Summary

As of 30-Sep-2026, Pasithea Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (29,190) 25,665 (5,372) (11,490)
Revenue 0 0 0 0
EBITDA (25,617) (20,092) (13,679) (15,275)
Net Income (24,834) (20,428) (13,905) (15,962)
Total Assets 46,490 60,240 16,065 26,117
Total Debt 0 0 0 82
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pasithea Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pasithea Therapeutics‘s full profile, request access.

Request a free trial

Pasithea Therapeutics Patents

Pasithea Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112507-A1 Tablet formulations and uses thereof Pending 22-Nov-2024
US-20260193221-A1 Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same Pending 19-Nov-2024
WO-2025230866-A1 Anti-alpha5 integrin antibodies and uses thereof Pending 29-Apr-2024
AU-2025205728-A1 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same Pending 05-Jan-2024
EP-4836956-A1 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same Pending 05-Jan-2024 A61P35/00
To view Pasithea Therapeutics’s complete patent history, request access »

Pasithea Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pasithea Therapeutics Acquisitions (2)

Pasithea Therapeutics’s most recent deal was a Merger/Acquisition with AlloMEK Therapeutics for . The deal was made on 11-Oct-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AlloMEK Therapeutics 11-Oct-2022 Merger/Acquisition Biotechnology
Alpha-5 Integrin 21-Jun-2022 Merger/Acquisition Biotechnology
To view Pasithea Therapeutics’s complete acquisitions history, request access »

Pasithea Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Pasithea Therapeutics’s complete esg history, request access »

Pasithea Therapeutics FAQs

  • When was Pasithea Therapeutics founded?

    Pasithea Therapeutics was founded in 2020.

  • Where is Pasithea Therapeutics headquartered?

    Pasithea Therapeutics is headquartered in Miami Beach, FL.

  • What is the size of Pasithea Therapeutics?

    Pasithea Therapeutics has 5 total employees.

  • What industry is Pasithea Therapeutics in?

    Pasithea Therapeutics’s primary industry is Drug Discovery.

  • Is Pasithea Therapeutics a private or public company?

    Pasithea Therapeutics is a Public company.

  • What is Pasithea Therapeutics’s stock symbol?

    The ticker symbol for Pasithea Therapeutics is KTTA.

  • What is the current stock price of Pasithea Therapeutics?

    As of 19-Nov-2026 the stock price of Pasithea Therapeutics is $0.47.

  • What is the current market cap of Pasithea Therapeutics?

    The current market capitalization of Pasithea Therapeutics is $17.7M.

  • What is Pasithea Therapeutics’s annual earnings per share (EPS)?

    Pasithea Therapeutics’s EPS for 12 months was -$1.38.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process